Barbara J. Klencke
Independent DirectorDr. Barbara J. Klencke, M.D., is Chief Medical Officer of ALX Oncology Holdings Inc. since February 25, 2026 and served as its Interim Chief Medical Officer from September 2025 to February 25, 2026. Dr. Klencke was Independent Director of ALX Oncology Holdings Inc. from January 18, 2025 to September 2025. Dr. Klencke is Independent Director of ALX Oncology Holdings Inc since January 18, 2025. She is Director of Xencor, Inc. since September 2023. She serves as an Independent Director at TScan Therapeutics, Inc. since April 2023. She served as Chief Medical Officer at Sierra Oncology, Inc. since May 2021. Dr. Klencke serves as a Director at Immune-Onc Therapeutics, Inc., since November 2022 and serves as its Chief Medical Advisor from 2023. Dr. Klencke has served as an independent board member of Lexent Bio, Inc. from 2017 until the companys acquisition by Foundation Medicine, Inc. in 2020. She had been the Chief Development Officer of Sierra Oncology, Inc. since June 2015 until its was acquired by GlaxoSmithKline in 2022. Dr. Klencke served as an Independent Director of eFFECTOR Therapeutics, Inc. since November 01, 2021 until June 21, 2024. Dr. Klencke served as Senior Vice President of Development at Onyx Pharmaceuticals, Inc., a subsidiary of Amgen Inc., from January 2011 to June 2015. Dr. Klencke was responsible for the development functions of Biometrics, Clinical Operations, Clinical Science, Medical Writing, Regulatory Affairs and Project Management. Dr. Klencke is an accomplished oncology drug developer with a demonstrable track record of success, having made substantial contributions to the development and approval of numerous significant oncology products, including Kyprolis, Kadcyla, Avastin and Tarceva. She joined Onyx in 2011 and served as Group Medical Director in Product Development, Oncology at Genentech, Inc. from July 2003 to January 2011, where she led clinical teams on molecules that have since made great advances for patients as marketed oncology medicines. She joined the Genentech in July 2003. Dr. Klencke served as Medical Director of Chiron Corporation and as an Assistant Professor of Medicine in Oncology, focusing on clinical research at the University of California, San Francisco Medical Center from 1995 to 2002. Her interest in drug development began after a long year career delivering patient care, initially in nursing and then in medicine, including many years teaching medicine and pursing clinical research at the University of California at San Francisco, where she also completed her training in Internal Medicine, Hematology and Oncology. Dr. Klencke earned her Doctor of Medicine at the University of California at Davis and her BS in Nursing from Indiana University at Bloomington.
Positions
- Company NameXencor, Inc.Stock CodeXNCRPositionIndependent DirectorColleagues
- BIBassil I. DahiyatCo-Founder, CEO, President & Director
- BJBart Jan CornelissenSenior VP & CFO
- JRJohn R. DesjarlaisExecutive VP of Research & Chief Scientific Officer
- CECelia E. EckertSenior VP, General Counsel & Corporate Secretary
- CLCharles LilesAssociate Director and Head of Corporate Communications & Investor Relations
- KAKurt A. GustafsonIndependent Director
- RJRichard J. RanieriIndependent Director
- BJBarbara J. KlenckeIndependent Director
- ABAlan Bruce Montgomerylead Independent Director
- Company NameALX Oncology Holdings Inc.Stock CodeALXOPositionChief Medical OfficerColleagues
- JWJason W. LettmannCEO & Director
- SGScott GarlandIndependent Chairman
- HSHarish ShantharamChief Financial Officer
- SWShelly WongSenior VP of Finance & Chief Accounting Officer
- JEJeff E. KnightChief Development & Operating Officer
- RHRekha HemrajaniIndependent Director
- KTKeith T. FlahertyChair of the Scientific Advisory Board
- CHChris H. TakimotoIndependent Director
